List of Excipients in Branded Drug METADATE ER

Generic Drugs Containing METADATE ER

Company	Ingredient	NDC	Excipient
Lannett Company Inc	methylphenidate hydrochloride	0527-2562	ANHYDROUS LACTOSE
Lannett Company Inc	methylphenidate hydrochloride	0527-2562	CETYL ALCOHOL
Lannett Company Inc	methylphenidate hydrochloride	0527-2562	ETHYLCELLULOSE
Lannett Company Inc	methylphenidate hydrochloride	0527-2562	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in METADATE ER?

# Of NDCs	Excipient
3	ANHYDROUS LACTOSE
3	CETYL ALCOHOL
2	ETHYLCELLULOSE
1	ETHYLCELLULOSES

METADATE ER Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 5, 2026

Metadate ER is an extended-release oral tablet containing methylphenidate hydrochloride, a Schedule II central nervous system stimulant used primarily for attention-deficit/hyperactivity disorder. Its commercial opportunity is driven less by novel active-ingredient protection and more by controlled-release performance, manufacturing reliability, generic competition, supply continuity, and differentiated dosage forms.

The most attractive excipient strategies are matrix systems that reproduce the reference product's release profile, improve tablet robustness, reduce dose-dumping risk, and support lower-cost manufacturing. Liquid, sprinkle, orally disintegrating, and abuse-deterrent products offer larger differentiation opportunities but require new clinical, bioequivalence, and regulatory work.

What is Metadate ER and how does its formulation work?

Metadate ER contains methylphenidate hydrochloride in an extended-release tablet. The product is intended to provide sustained drug exposure over the school or working day while reducing the dosing frequency associated with immediate-release methylphenidate tablets.

Product attribute	Metadate ER profile
Active ingredient	Methylphenidate hydrochloride
Dosage form	Extended-release oral tablet
Controlled substance	Schedule II
Primary indication	ADHD
Reference regulatory pathway	NDA drug product
Administration	Oral, generally once daily
Primary formulation challenge	Reproducing the reference dissolution profile
Key commercial substitutes	Immediate-release methylphenidate, Concerta, Metadate CD, Ritalin LA, generic extended-release methylphenidate

Metadate ER should be distinguished from Metadate CD. Metadate CD uses a multiparticulate capsule design, while Metadate ER is an extended-release tablet. The products therefore create different formulation, bioequivalence, manufacturing, and patient-use considerations.

The tablet's commercial value depends on release control rather than on excipient novelty. A typical extended-release methylphenidate tablet may use a hydrophilic or hydrophobic matrix, compression-controlled porosity, polymeric coating, or a combination of these technologies. The exact quantitative composition and manufacturing parameters of the reference product determine the relevant development target and cannot be inferred reliably from the public label alone.

What excipients are used in Metadate ER?

Public labeling identifies inactive ingredients, but generally does not disclose their quantitative levels, particle-size specifications, granulation endpoint, compression force, coating parameters, or dissolution-control process. Those undisclosed elements may have greater commercial importance than the excipient names themselves.

Publicly reported inactive ingredients for extended-release methylphenidate tablet products have included combinations of the following:

Excipient class	Potential function in Metadate ER-type tablets	Commercial relevance
Lactose or lactose monohydrate	Diluent and compressibility aid	Low cost; potential relevance for lactose-sensitive patients
Microcrystalline cellulose	Binder, filler, and tablet-strength contributor	Supports direct compression or granulation
Povidone	Binder and granulation aid	Influences hardness, porosity, and dissolution
Magnesium stearate	Lubricant	Excessive levels can slow wetting and dissolution
Talc	Processing aid or anti-adherent	May affect powder flow and tablet surface properties
Stearic acid or related hydrophobic excipients	Release modulation and lubrication	Can reduce water penetration and slow drug release
Colloidal silicon dioxide	Glidant and flow aid	Helps control blend uniformity and compression
Film-coating materials	Appearance, handling, and moisture protection	May affect mechanical durability and limited release behavior

Formulators should treat the public inactive-ingredient listing as a starting point, not as a complete reverse-engineering profile. The relevant intellectual property and regulatory differentiation may reside in excipient ratios, polymer grades, particle-size distributions, granulation conditions, coating weight, tablet porosity, and dissolution controls.

What excipient strategy is best for a generic Metadate ER product?

A generic developer should prioritize a robust matrix platform that can match the reference product across the full dissolution curve, not only at a small number of regulatory sampling points.

Matrix design

A hydrophilic matrix based on hypromellose or a comparable release-controlling polymer can provide a scalable platform. The main variables include:

• Polymer viscosity grade
• Polymer concentration
• Drug-to-polymer ratio
• Tablet porosity
• Compression force
• Granule density
• Lubrication level
• Tablet dimensions
• Coating permeability

A hydrophobic matrix using stearic acid, glyceryl behenate, waxes, or related materials may provide stronger resistance to rapid liquid ingress. It can also create more difficult scale-up and dissolution-correlation issues.

Release-profile control

Methylphenidate extended-release products are sensitive to formulation and process changes. A commercial formulation should be tested under:

• Multiple dissolution media and pH conditions
• Agitation rates
• Fed and fasted conditions
• Alcohol-containing media
• Mechanical stress and tablet abrasion
• Long-term and accelerated stability
• Dose proportionality across available strengths

Alcohol-induced dose dumping is a specific risk for modified-release products. FDA guidance identifies alcohol effects, agitation sensitivity, and food effects as important considerations for extended-release and delayed-release products.[1]

Excipient selection criteria

The preferred excipient package should have:

1. A strong regulatory history in oral extended-release products.
2. Multiple qualified suppliers.
3. Low variability in particle size and moisture.
4. Compatibility with methylphenidate hydrochloride.
5. Stable compression and ejection performance.
6. A dissolution profile that remains consistent after scale-up.
7. A low risk of nitrosamine, elemental impurity, or microbial-control complications.

Supplier redundancy matters because methylphenidate products have experienced supply interruptions. A formulation dependent on one proprietary polymer grade or one specialized excipient supplier has greater business continuity risk.

What formulation patents protect Metadate ER?

The core methylphenidate molecule is long off patent. The commercial protection historically associated with Metadate ER would have related primarily to the dosage form, release mechanism, manufacturing process, or method of use rather than to methylphenidate itself.

Protection category	Relevance to Metadate ER
Active-ingredient patent	No meaningful current protection for methylphenidate hydrochloride
Extended-release formulation patent	Potentially relevant historically, but legacy rights are unlikely to block ordinary generic entry if expired
Manufacturing patent	Could matter if a specific granulation, coating, or matrix process remains enforceable
Method-of-use patent	Limited relevance if directed to established ADHD treatment claims
Orange Book-listed patent	Must be checked against the current FDA Orange Book for the applicable NDA
Trade secret	Quantitative formula, process controls, and dissolution specifications may remain commercially important

The FDA Orange Book is the controlling public source for listed patents and exclusivity associated with an approved reference drug.[2] A developer should not assume that the absence of a publicly visible formulation patent eliminates all competitive barriers. Manufacturing know-how, supplier qualifications, bioequivalence data, and regulatory timing can still delay market entry.

When did Metadate ER lose exclusivity?

Metadate ER is a legacy methylphenidate product, and any original regulatory exclusivity or composition-of-matter protection has expired. The competitive question is therefore generic substitution and formulation differentiation, not basic active-ingredient exclusivity.

The relevant current checks are:

• Whether the reference NDA remains active.
• Whether the product is listed as currently marketed.
• Whether FDA has listed patents or exclusivity for the reference NDA.
• Whether approved ANDAs have therapeutic-equivalence ratings.
• Whether any current patent litigation affects an ANDA applicant.
• Whether supply shortages create temporary commercial openings.

Paragraph IV risk for a new Metadate ER generic would generally arise from a patent certification against any currently listed patent. For a legacy product with no meaningful unexpired listed protection, the greater risk is regulatory failure, inadequate bioequivalence, manufacturing delay, or inability to obtain reliable methylphenidate supply.

What is the Orange Book status of Metadate ER?

The Orange Book should be reviewed using the exact reference product name, NDA number, strength, and dosage form. Metadate ER has a long regulatory history, and historical listings may not reflect current commercial marketing.

Orange Book issue	Business implication
Reference listed drug status	Determines the product used for ANDA comparison
Active NDA status	Affects the relevant abbreviated-application pathway
Listed patents	Determines Paragraph III or Paragraph IV strategy
Therapeutic-equivalence codes	Indicates whether approved generics are substitutable
Discontinued or withdrawn status	May affect RLD selection and applicant strategy
Strength-specific listing	Bioequivalence and labeling requirements may differ by strength

An applicant should verify the current FDA database rather than rely on historical product directories. The FDA also publishes guidance on determining the reference listed drug and pharmaceutical equivalence requirements for generic applications.[3]

How many patents cover Metadate ER?

The active-ingredient patent count is effectively zero for current commercial purposes. The important count is the number of unexpired, enforceable patents listed against the relevant reference NDA. That number must be determined from the current Orange Book entry and associated patent records.

Historical patents may include claims directed to:

• Extended-release methylphenidate tablets
• Polymer-based release systems
• Specific release rates
• Tablet coatings
• Multiparticulate or bead technologies
• Administration schedules
• Abuse-deterrent delivery systems

A patent that covers another methylphenidate product, such as Concerta or Metadate CD, does not automatically cover Metadate ER. Product-specific claim scope matters.

Which companies compete with Metadate ER?

Metadate ER competes across several release technologies rather than against a single product.

Competitor	Active ingredient	Dosage form or technology	Competitive issue
Generic methylphenidate ER	Methylphenidate HCl	Extended-release tablet	Price competition and substitution
Concerta	Methylphenidate HCl	Osmotic extended-release tablet	Longer duration and differentiated release profile
Metadate CD	Methylphenidate HCl	Extended-release capsule with multiparticulates	Capsule opening and sprinkle potential
Ritalin LA	Methylphenidate HCl	Biphasic bead-based capsule	Two-pulse exposure profile
Quillivant XR	Methylphenidate HCl	Extended-release oral suspension	Pediatric and swallowing differentiation
Daytrana	Methylphenidate	Transdermal patch	Nonoral delivery and titratability
Azstarys	Serdexmethylphenidate/dexmethylphenidate	Capsule	Prodrug and immediate-release combination
Immediate-release methylphenidate	Methylphenidate HCl	Tablet or solution	Lower cost but more frequent dosing

The strongest direct pressure comes from generic extended-release methylphenidate tablets. The strongest formulation-based alternatives are liquid, transdermal, multiparticulate, and osmotic systems.

What commercial opportunities exist for Metadate ER excipients?

Authorized generic or low-cost generic

The lowest-risk opportunity is a conventional extended-release tablet using widely accepted excipients. The value proposition is manufacturing efficiency, reliable supply, and competitive pricing.

Potential advantages include:

• Fewer specialized excipients
• Direct-compression manufacturing
• Two-source supply for each critical ingredient
• Reduced coating complexity
• Robust dissolution after scale-up
• Compatibility with standard controlled-substance manufacturing

This strategy is unlikely to command a substantial premium but can generate volume if supply reliability is strong.

Lactose-free or low-lactose formulation

A lactose-free version could address excipient sensitivity and expand formulary options. The commercial value is limited unless the product also improves swallowing, tolerability, or availability. Mannitol, dibasic calcium phosphate, or alternative cellulose-based fillers could replace lactose, but each substitution requires dissolution and bioequivalence assessment.

Sprinkle or mini-tablet formulation

A capsule containing coated multiparticulates or mini-tablets would address pediatric patients who cannot swallow conventional tablets. It would compete more directly with Metadate CD and Ritalin LA than with the existing Metadate ER tablet.

The main technical barriers are:

• Uniform drug loading across particles
• Coating reproducibility
• Dose delivery after opening the capsule
• Food and beverage compatibility
• Mechanical resistance during handling
• Alcohol and chewing studies
• Packaging and moisture control

Extended-release oral suspension

An oral suspension could provide flexible dosing and pediatric utility. However, methylphenidate suspension development requires control of sedimentation, redispersibility, dose uniformity, preservative performance, taste, and in-use stability. The product would compete with Quillivant XR and would likely require a differentiated clinical or patient-use proposition.

Abuse-deterrent formulation

Methylphenidate is a controlled substance with diversion and misuse concerns. A tamper-resistant matrix or abuse-deterrent formulation could create value, but the regulatory and development burden is high. FDA's abuse-deterrent guidance expects meaningful evidence against specified manipulation routes and does not grant a broad presumption of abuse prevention.[4]

Potential technologies include:

• Increased tablet hardness
• Gel-forming polymers
• Crush-resistant matrices
• Aversion agents
• Reduced extractability
• Physical barriers to pulverization

A developer should avoid assuming that a harder tablet alone creates a commercially defensible abuse-deterrent product.

What manufacturing and IP barriers affect Metadate ER?

The principal barriers are process and regulatory barriers rather than active-ingredient patent barriers.

Manufacturing barriers

• Controlled-substance inventory and security requirements
• Tight content-uniformity controls
• Blend segregation risk
• Compression variability
• Lubrication-related dissolution shifts
• Dose dumping under alcohol exposure
• Tablet breakage and friability
• Supply interruptions affecting polymers or lubricants
• Scale-up changes in granule density and porosity

Intellectual-property barriers

• Unexpired formulation claims
• Process patents covering matrix formation
• Coating patents
• Drug-release profile claims
• Abuse-deterrent claims
• Trade-secret process parameters
• Patent rights associated with a differentiated follow-on product

Regulatory barriers

• ANDA bioequivalence
• Comparative dissolution
• Food-effect assessment
• Labeling alignment
• Controlled-substance registration
• Manufacturing-site inspection
• Stability data
• Drug Master File access for proprietary excipients

What generic launch scenarios exist for Metadate ER?

Launch scenario	Timing and risk profile	Commercial outcome
Conventional ANDA tablet	Lowest development complexity	Rapid price erosion after multiple approvals
Paragraph III launch	Delayed until listed patent expiry	Lower litigation exposure
Paragraph IV launch	Earlier launch possibility	Litigation and 30-month-stay risk if applicable
Authorized generic	Lower patent and substitution risk	Moderate margin, stronger distribution
505(b)(2) sprinkle product	Higher development burden	Potential pediatric and adherence premium
Oral suspension	Significant formulation and clinical work	Differentiated but crowded market
Abuse-deterrent product	Highest technical and regulatory risk	Possible premium if labeling and payer coverage support it

For a conventional tablet, first-mover timing matters. A launch before broad generic penetration can obtain temporary volume, but methylphenidate markets can experience rapid price compression once several therapeutically equivalent products enter.

How strong is the Metadate ER patent estate?

The patent estate is weak as a barrier to conventional generic entry because methylphenidate is an old active ingredient and Metadate ER is a legacy extended-release product. The defensible commercial assets are more likely to be:

• Manufacturing consistency
• Bioequivalence data
• Supply capacity
• Product availability
• Pediatric usability
• Formulation know-how
• Distribution contracts
• Any current, product-specific formulation claims

A new entrant should allocate more resources to dissolution matching, controlled-substance operations, and reliable supply than to broad composition-of-matter patenting.

What licensing deals and litigation affect Metadate ER?

No major current licensing or litigation relationship can be established from the core public product information alone. Methylphenidate products have been involved in broader patent disputes, especially where extended-release delivery technologies are concerned, but litigation involving Concerta, Metadate CD, Ritalin LA, or another methylphenidate product should not be attributed to Metadate ER without a product-specific docket and patent claim analysis.

The relevant diligence targets are:

• FDA Orange Book patent listings
• ANDA applicant notices
• District court complaints
• Hatch-Waxman settlement agreements
• Federal Circuit decisions
• Controlled-substance manufacturing arrangements
• Authorized-generic supply agreements

Key Takeaways

• Metadate ER is an extended-release methylphenidate hydrochloride tablet with limited current active-ingredient exclusivity.
• Its principal formulation value lies in controlled release, dissolution reproducibility, and manufacturing process control.
• Generic opportunities are strongest for a conventional tablet with reliable supply and low manufacturing cost.
• Larger differentiation opportunities exist in sprinkle, mini-tablet, oral suspension, lactose-free, and abuse-deterrent formats.
• The public inactive-ingredient list does not disclose the quantitative formulation or process conditions that determine bioequivalence.
• The current Orange Book entry, not historical patent records, controls the analysis of listed patents and Paragraph IV exposure.
• Patent barriers are likely weaker than regulatory, manufacturing, controlled-substance, and supply-chain barriers.
• Competitive pressure comes from generic methylphenidate ER tablets, Concerta, Metadate CD, Ritalin LA, Quillivant XR, Daytrana, and newer methylphenidate-based products.

FAQs About Metadate ER Excipient and Commercial Strategy

Can lactose be removed from a Metadate ER generic?

Yes. Lactose can be replaced with mannitol, microcrystalline cellulose, calcium phosphate, or another suitable diluent, but the change must be evaluated for tablet strength, dissolution, stability, and bioequivalence.

Is hypromellose required for an extended-release methylphenidate tablet?

No. Hypromellose is one possible release-controlling polymer. Hydrophobic matrices, coated particles, osmotic systems, and other technologies may also control methylphenidate release.

Can Metadate ER be converted into a chewable tablet?

A chewable product would be a new formulation project. Chewing could destroy the intended release mechanism, so the product would require separate performance, stability, palatability, and regulatory evidence.

Does a generic Metadate ER tablet need to match the brand's excipients?

No. FDA generic requirements generally focus on pharmaceutical equivalence, bioequivalence, quality, and comparable labeling requirements. An applicant can use different inactive ingredients if they are suitable and do not affect safety, performance, or regulatory compliance.[3]

Would a new Metadate ER formulation qualify for three-year exclusivity?

Potentially, but only if it obtains approval for a new clinical investigation essential to approval and satisfies FDA's statutory exclusivity requirements. A routine generic formulation change normally does not create three-year exclusivity.

References

1. U.S. Food and Drug Administration. (2002). Guidance for industry: Extended release solid oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. FDA.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2015). Guidance for industry: ANDAs for certain highly variable drugs. FDA.

4. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. FDA.

5. National Library of Medicine. (2024). DailyMed: Metadate ER and methylphenidate hydrochloride extended-release tablet labeling. U.S. National Library of Medicine.